Quotidian Hemodialysis and Inflammation Associated With Chronic Kidney Disease

Advances in Chronic Kidney Disease

Volumn 14, Issue 3, 2007, Pages

  Hamlett, Leslie ^a   Haragsim, Lukas ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

chronic kidney disease; cytokine; hemodialysis; Inflammation; quotidian

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DAILY NOCTURNAL HEMODIALYSIS; DISEASE ASSOCIATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SHORT DAILY HEMODIALYSIS; TREATMENT DURATION; UNITED STATES;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MULTICENTER STUDIES; OXIDATIVE STRESS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 34250847659     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2007.03.006     Document Type: Article

References (74)

1. US Renal Data System: USRDS 2006 Annual Data Report (2006), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
2. Foley R., Parfrey P., and Sarnak M. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9 suppl 12 (1998) S16-S23
3. Kim B.S., Jeon D.S., Shin M.J., et al. Persistant elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol 25 (2005) 189-195
4. Goodman W.G. Vascular calcification in end-stage renal disease. J Nephrol 15 suppl 6 (2002) S82-S85
5. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and rennin-angiotensin system. Atheroscler Thromb Vasc Biol 22 (2002) 1257-1266
6. Foley R.N., Parfrey P.S., Harnett J.D., et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996) 53-61
7. Goicoechea M., Martin J., de Sequera P., et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54 (1998) 1337-1343
8. Stenvinkel P., Lindholm B., and Heimburger O. Novel approaches on an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dialysis 17 (2004) 505-515
9. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
10. Stedman T.L. Stedman's Medical Dictionary. (ed 26) (1995), Williams and Wilkins, Baltimore, MD 869
11. Pecoits-Filho R., Heimburger O., Barany P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 (2003) 1212-1218
12. Urieli-Shoval S., Linke R., and Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7 (2000) 64-69
13. Bathon J., Graves J., Jens P., et al. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis 10 (1987) 34-40
14. Ortega O., Rodriguez I., Gallar P., et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17 (2002) 1105-1109
15. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
16. Yeun J.Y., Levine R.A., Mantadilok V., et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35 (2000) 469-476
17. Memoli B., Libetta C., Rampino T., et al. Hemodialysis-related induction of interleukin-6 production by peripheral blood mononuclear cells. Kindey Int 42 (1992) 320-326
18. Liu Y., Berthier-Schaad Y., Fallin M.D., et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 17 (2006) 863-870
19. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
20. Pecoits-Filho R., Barany P., Lindholm B., et al. Interleukin-6 is an independent predictor in mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17 (2002) 1684-1688
21. Conti G., Amore A., Chiesa M., et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol 18 (2005) 282-288
22. Stenvinkel P., Ketteler M., Johnson R.J., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-The good, the bad, and the ugly. Kidney Int 67 (2005) 1216-1233
23. Pereira B.J., Shapiro L., King A.J., et al. Plasma levels of IL-1 beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney Int 45 (1994) 890-896
24. Seyrek N., Karayaylali I., Balal M., et al. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients?. Scand J Urol Nephrol 39 (2005) 405-409
25. Kalousova M., Zima T., and Tesar V. Carbonyl stress and chronic renal failure. Casopis Lekaru Ceskych 141 (2002) 143-145
26. Miyata T., Oda O., Inagi R., et al. Beta 2-microglobulin modified with advanced glycation end product is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92 (1993) 1243-1252
27. Morena M., Dilbosc S., Dupuy A., et al. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis associated inflammation. Hemodialysis Int 9 (2005) 37-46
28. Sela S., Shurtz-Swirski R., Cohen-Mazor M., et al. Primed peripheral polymorphonuclear leukocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16 (2005) 2431-2438
29. Babior B.M. NADPH oxidase: An update. Blood 93 (1999) 1464-1476
30. Brennan M.L., and Hazen S.L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 14 (2003) 353-359
31. Miyata T., Ueda Y., Horie K., et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 53 (1998) 416-422
32. Sharma R., Bolger A.P., Li W., et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 92 (2003) 188-193
33. Kjellstrand C.M., Evans R.L., Peterson R.J., et al. The "unphysiology" of dialysis: A major cause of dialysis side effects?. Kidney Int 7 (1975) S30-S34
34. Lindsay R.M., Leitch R., Heidenheim A., et al. The London Daily/Nocturnal Hemodialysis Study-Study design,morbidity, and mortality results. Am J Kidney Dis 42 suppl 1 (2003) 5-12
35. Woods J.D., Port F.K., Orzol S., et al. Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 55 (1999) 2467-2476
36. Nesrallah G., Suri R., Moist L., et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42 (2003) 13-17
37. Fagugli R.M., Reboldi G., and Quintaliani G. Short daily dialysis: Blood pressure control and left ventricular mass reduction in hypertensive patients. Am J Kidney Dis 38 (2001) 371-376
38. Mahmud A., and Freely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 46 (2005) 1118-1122
39. Ayus J.C., Mizani M.R., Achinger S.G., et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective controlled study. J Am Soc Nephrol 16 (2005) 2778-2788
40. Chan C.T., Floras J.S., Miller J.A., et al. Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 17 (2002) 1518-1521
41. Torun D., Sezer S., Baltali M., et al. Association of cardiac valve calcification and inflammation in patients on hemodialysis. Ren Fail 27 (2005) 221-226
42. Chan C.T., Li S.H., and Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 289 (2005) F679-F684
43. Verma S., Kuliszewski M.A., Li S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
44. Jofre R., Rodriguez-Benitez P., Lopez-Gomez J., et al. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 17 (2006) 274-280
45. Nadra I., Mason J., Phillippides P., et al. Proinflammatory activation of macrophages by basic calcium phosphate crystal via protein kinase C and MAP kinase pathways. A vicious cycle of inflammation and arterial calcification. Circ Res 96 (2005) 1248-1256
46. Chan C.T., Mardirossian S., Faratro R., et al. Improvement of lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis 41 (2003) 225-229
47. Kaysen G., and Elserich J.P. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial 16 (2003) 438-446
48. Bugeja A.L., and Chan C.T. Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. Trans Am Soc Artif Intern Organs 50 (2004) 328-331
49. Trey J.E., and Kushner I. The acute phase response and the hemotopoietic system. The role of cytokines. Crit Rev Oncol Hematol 21 (1995) 1-18
50. Yuen D., Richardson R., Fenton S., et al. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Trans Am Soc Artif Intern Organs 51 (2005) 236-241
51. Schwartz D.I., Pierratos A., Richardson R.M., et al. Impact of nocturnal hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 63 (2005) 202-208
52. Beddhu S., Kaysen G.A., Yan G., et al., HEMO Study Group. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 40 (2002) 721-727
53. Beddhu S., Pappas L.M., Ramkumar N., et al. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 15 (2004) 733-742
54. Eustace J.A., Astor B., Muntner P.M., et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 65 (2004) 1031-1040
55. Suliman M.E., Heimburger O., Barany P., et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 14 (2003) 1614-1622
56. Fagugli R.M., Vanholder R., De Smet R., et al. Advanced glycation end products: Specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs 24 (2001) 256-262
57. Ikizler T.A., Flakoll P.J., Parker R.A., et al. Amino acid and albumin losses during hemodialysis. Kidney Int 46 (1994) 830-837
58. Pierratos A. Nocturnal home hemodialysis: An update on a 5-year experience. Nephrol Dial Transplant 14 (1999) 2835-2840
59. Galland R., Traeger J., Arkouche W., et al. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int 60 (2001) 1555-1560
60. Wiggins K.J., Somerville C.A., Knight R., et al. Intradialytic protein concentrations differ between nightly nocturnal and conventional hemodialysis. Nephrology 10 (2005) 325-329
61. Spanner E., Suri R., Heidenheim A.P., et al. The impact of quotidian hemodialysis on nutrition. Am J Kidney Dis 42 suppl 1 (2003) 30-35
62. Lindsay R.M., Nesrallah G., Suri R., et al. Is more frequent hemodialysis beneficial and what is the evidence?. Curr Opin Nephrol Hypertens 13 (2004) 631-635
63. Nokher W., and Scherberich J. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 48 (1995) 1469-1476
64. Griveas I., Visvardis G., Sakellariou G., et al. Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers. Ren Fail 28 (2006) 493-499
65. Korevaar J.C., van Manen J.G., Dekker F.W., et al., NECOSAD Study Group. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 15 (2004) 2916-2922
66. Azevedo S.M., Carmichael W.W., Jochimsen E.M., et al. Human intoxication by microcystins during renal dialysis treatment in Caruaru-Brazil. Toxicology 181 (2002) 441-446
67. Hoenich N.A., and Levin R. The implication of water quality in hemodialysis. Semin Dial 16 (2003) 492-497
68. Schiffl H., Lang S.M., Stratakis D., et al. Effect of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 16 (2001) 1863-1869
69. Ward R.A. Ultrapure dialysate. Semin Dial 17 (2004) 489-497
70. Lederer S.R., and Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by continuous microinflammation. Nephron 91 (2002) 452-455
71. Lamas J.M., Alonso M., Sastre F., et al. Ultrapure dialysate and inflammatory response in hemodialysis evaluated by darbepoetin requirements-A randomized study. Nephrol Dial Transplant 21 (2006) 2851-2858
72. Amore A., Cirina P., Bonaudo R., et al. Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. J Nephrol 19 (2006) 57-64
73. Kaysen G.A. The microinflammatory state in uremia and causes and potential consequences. J Am Soc Nephrol 12 (2001) 1549-1557
74. Piccoli G.B., Bermond F., Mezza E., et al. Vascular access survival and morbidity on daily dialysis: A comparative analysis of home and limited care hemodialysis. Nephrol Dial Transplant 19 (2004) 2084-2094